Advertisement

Topics

Entrectinib May Have a Future Beyond Pediatric Relapsed/Refractory Solid Tumors

14:50 EDT 13 Jul 2018 | OncLive

Ami Vijay Desai, MD, discusses the ideal patient population for entrectinib and what the future could hold for the agent.

Original Article: Entrectinib May Have a Future Beyond Pediatric Relapsed/Refractory Solid Tumors

NEXT ARTICLE

More From BioPortfolio on "Entrectinib May Have a Future Beyond Pediatric Relapsed/Refractory Solid Tumors"

Advertisement
Quick Search
Advertisement
Advertisement